101
|
Fujii H, Watano S. Development of Universal Formulation with Superior Re-dispersion Using Nanocrystal Approach with Simultaneous Identification of API Physicochemical Properties. Chem Pharm Bull (Tokyo) 2019; 67:1050-1060. [PMID: 31582625 DOI: 10.1248/cpb.c19-00092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Universal nanocrystal formulation which can be applied to water-insoluble compounds was proposed and the criteria of its physicochemical properties as an active pharmaceutical ingredients (API) were investigated. Nanocrystal suspension was prepared by a wet-beads milling method. An acceptable Critical Quality Attributes (CQA) of nanocrystal suspension was defined by Z-average less than 500 nm and Polydispersity index (PDI) less than 0.3. Screening studies of dispersing and wetting agents were conducted using three model compounds in different pKa, melting points, etc., to find universal nanocrystal formulation. The effect of four structurally different polymer species (hydroxypropyl cellulose (HPC), hydoroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA)) and their different grades or five different surfactants (docusate sodium (DOSS), sodium lauryl sulfate (SLS), cetyl trimethyl ammonium bromide (CTAB), polysolbate80 (PS80), and polyoxyethylene castor oil (CO-35)) were studied on the re-dispersion stability. It was found that the combination of 4% (w/v) HPC-SSL and 0.2% (w/v) DOSS was the most robust nanocrystal formulation owing to Z-average less than 200 nm and good re-dispersion stability without aggregates at pH 1.2 and pH 6.8. API physicochemical properties were also identified using ten water-insoluble compounds. Consequently, it was found that solubility (water, pH 1.2 and pH 6.8), molecular weight, hydrogen bonding acceptor and the ratio of log D7.4 to C Log P were critical factors.
Collapse
Affiliation(s)
- Hiroyuki Fujii
- Department of Chemical Engineering, Graduate School of Engineering, Osaka Prefecture University
| | - Satoru Watano
- Department of Chemical Engineering, Graduate School of Engineering, Osaka Prefecture University
| |
Collapse
|
102
|
Zhao J, Yang J, Xie Y. Improvement strategies for the oral bioavailability of poorly water-soluble flavonoids: An overview. Int J Pharm 2019; 570:118642. [DOI: 10.1016/j.ijpharm.2019.118642] [Citation(s) in RCA: 135] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 08/20/2019] [Accepted: 08/21/2019] [Indexed: 01/29/2023]
|
103
|
The prospects of lipidic prodrugs: an old approach with an emerging future. Future Med Chem 2019; 11:2563-2571. [DOI: 10.4155/fmc-2019-0155] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Nowadays, prodrugs are no longer used as a last resort, rather, they are intentionally designed at the early stages of drug development. Lipidic prodrug strategy, where a drug moiety is covalently bound to a lipid carrier, was initially proposed half a century ago, yet, this approach still remains to be explored. Lipidic prodrugs can join physiological lipid metabolic pathways, and hence provide drug targeting via lymphatic transport or site-specific drug release, improve drugs’ pharmacokinetic profile, overcome obstacles originating from biological barriers and bypass hepatic first-pass metabolism. Physiological pathways of lipid processing, uses of different lipidic prodrugs and their clinical benefits are overviewed. Overall, lipidic prodrugs present a promising approach for overcoming different obstacles and fulfilling various unmet needs in drug delivery/targeting.
Collapse
|
104
|
Saw PE, Yao H, Lin C, Tao W, Farokhzad OC, Xu X. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy. NANO LETTERS 2019; 19:5967-5974. [PMID: 31381852 DOI: 10.1021/acs.nanolett.9b01660] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Nanoparticles (NPs) formulated with cationic lipids and/or polymers have shown substantial potential for systemic delivery of RNA therapeutics such as small interfering RNA (siRNA) for the treatment of cancer and other diseases. While both cationic lipids and polymers have demonstrated the promise to facilitate siRNA encapsulation and endosomal escape, they could also hamper cytosolic siRNA release due to charge interaction and induce potential toxicities. Herein, a unique polymer-prodrug hybrid NP platform was developed for multistage siRNA delivery and combination cancer therapy. This NP system is composed of (i) a hydrophilic polyethylene glycol (PEG) shell, (ii) a hydrophobic NP core made with a tumor microenvironment (TME) pH-responsive polymer, and (iii) charge-mediated complexes of siRNA and amphiphilic cationic mitoxantrone (MTO)-based prodrug that are encapsulated in the NP core. After intravenous administration, the long-circulating NPs accumulate in tumor tissues and then rapidly release the siRNA-prodrug complexes via TME pH-mediated NP disassociation for subsequent tissue penetration and cytosolic transport. With the overexpressed esterase in tumor cells to hydrolyze the amphiphilic structure of the prodrug and thereby induce destabilization of the siRNA-prodrug complexes, the therapeutic siRNA and anticancer drug MTO can be efficiently released in the cytoplasm, ultimately leading to the combinational inhibition of tumor growth via concurrent RNAi-mediated gene silencing and MTO-mediated chemotherapy.
Collapse
Affiliation(s)
- Phei Er Saw
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
- RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
| | - Herui Yao
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
- RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
| | - Chunhao Lin
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
- RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
| | - Wei Tao
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital , Harvard Medical School , Boston , Massachusetts 02115 , United States
| | - Omid C Farokhzad
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital , Harvard Medical School , Boston , Massachusetts 02115 , United States
| | - Xiaoding Xu
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
- RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou 510120 , P. R. China
| |
Collapse
|
105
|
Kwon J, Giri BR, Song ES, Bae J, Lee J, Kim DW. Spray-Dried Amorphous Solid Dispersions of Atorvastatin Calcium for Improved Supersaturation and Oral Bioavailability. Pharmaceutics 2019; 11:E461. [PMID: 31500147 PMCID: PMC6781288 DOI: 10.3390/pharmaceutics11090461] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 08/30/2019] [Accepted: 09/04/2019] [Indexed: 02/06/2023] Open
Abstract
Over the past few decades, the amorphous solid dispersions (ASDs) technique has emerged as a promising strategy to enhance the in vitro/in vivo characteristic of hydrophobic drugs. The low aqueous solubility and poor bioavailability of atorvastatin calcium (ATO), a lipid-lowering drug, present challenges for effective drug delivery. The objective of this work was to improve the aqueous solubility, in vitro dissolution, and oral absorption of ATO with amorphous solid dispersion technique prepared by spray-drying method. The optimized ternary formulation comprising of ATO; hydroxypropyl methylcellulose (HPMC), as a hydrophilic polymer; and sodium lauryl sulfate (SLS), as a surfactant, at a weight ratio of 1/1/0.1, showed significant improvement in aqueous solubility by ~18-fold compared to that of the free drug, and a cumulative release of 94.09% compared to a release of 59.32% of the free drug. Further, physicochemical studies via scanning electron microscopy, differential scanning calorimetry, and powder X-ray diffraction revealed a change from the crystalline state of the free drug to its amorphous state in the ASD. Pharmacokinetic analysis in rats demonstrated 1.68- and 2.39-fold increments in AUC and Cmax, respectively, in the ASD over the free drug. Altogether, hydrophilic carrier-based ASDs prepared by the spray-drying technique represent a promising strategy to improve the biopharmaceutical performance of poorly soluble drugs.
Collapse
Affiliation(s)
- Jaewook Kwon
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
| | - Bhupendra Raj Giri
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
| | - Eon Soo Song
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
| | - Jinju Bae
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
| | - Junseong Lee
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
| | - Dong Wuk Kim
- College of Pharmacy & Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.
| |
Collapse
|
106
|
Ho DK, Nichols BLB, Edgar KJ, Murgia X, Loretz B, Lehr CM. Challenges and strategies in drug delivery systems for treatment of pulmonary infections. Eur J Pharm Biopharm 2019; 144:110-124. [PMID: 31493510 DOI: 10.1016/j.ejpb.2019.09.002] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 08/23/2019] [Accepted: 09/03/2019] [Indexed: 01/08/2023]
Abstract
Inhalation therapy has been reported as the most effective treatment for respiratory bacterial infections due to the increasing relevance of drug bioavailability. Drug delivery systems (DDS) have the capacity to overcome pulmonary biological barriers limiting the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial infections and to prevent the development of bacterial resistance. Despite substantial efforts in the field, the current state-of-the-art often fails to achieve those goals, and we still observe increasing bacterial resistance. We give a brief insight on benefits and challenges in pulmonary delivery of anti-infectives. In the context of drug delivery development for pulmonary infections, particularly focusing on Pseudomonas aeruginosa (PA) infections, this mini review will critically discuss the main requirements, as well as the recent strategies of drug delivery system synthesis and preparation. Finally, interaction of DDS with crucial pulmonary biological barriers will be of great importance for the success of future applications of the developed DDS.
Collapse
Affiliation(s)
- Duy-Khiet Ho
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, D-66123 Saarbrücken, Germany
| | - Brittany L B Nichols
- Department of Chemistry, Virginia Tech, Blacksburg, VA 24061, United States; Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA 24061, United States
| | - Kevin J Edgar
- Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA 24061, United States; Department of Sustainable Biomaterials, Virginia Tech, Blacksburg, VA 24061, United States
| | - Xabier Murgia
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, D-66123 Saarbrücken, Germany
| | - Brigitta Loretz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, D-66123 Saarbrücken, Germany.
| | - Claus-Michael Lehr
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, D-66123 Saarbrücken, Germany; Department of Pharmacy, Saarland University, D-66123 Saarbrücken, Germany
| |
Collapse
|
107
|
Sanches BM, Ferreira EI. Is prodrug design an approach to increase water solubility? Int J Pharm 2019; 568:118498. [DOI: 10.1016/j.ijpharm.2019.118498] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 07/04/2019] [Accepted: 07/05/2019] [Indexed: 02/07/2023]
|
108
|
Soni D, Bade AN, Gautam N, Herskovitz J, Ibrahim IM, Smith N, Wojtkiewicz MS, Dyavar Shetty BL, Alnouti Y, McMillan J, Gendelman HE, Edagwa BJ. Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials 2019; 222:119441. [PMID: 31472458 DOI: 10.1016/j.biomaterials.2019.119441] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 08/04/2019] [Accepted: 08/19/2019] [Indexed: 01/20/2023]
Abstract
While antiretroviral therapy (ART) has revolutionized treatment and prevention of human immunodeficiency virus type one (HIV-1) infection, regimen adherence, viral mutations, drug toxicities and access stigma and fatigue are treatment limitations. These have led to new opportunities for the development of long acting (LA) ART including implantable devices and chemical drug modifications. Herein, medicinal and formulation chemistry were used to develop LA prodrug nanoformulations of emtricitabine (FTC). A potent lipophilic FTC phosphoramidate prodrug (M2FTC) was synthesized then encapsulated into a poloxamer surfactant (NM2FTC). These modifications extended the biology, apparent drug half-life and antiretroviral activities of the formulations. NM2FTC demonstrated a >30-fold increase in macrophage and CD4+ T cell drug uptake with efficient conversion to triphosphates (FTC-TP). Intracellular FTC-TP protected macrophages against an HIV-1 challenge for 30 days. A single intramuscular injection of NM2FTC, at 45 mg/kg native drug equivalents, into Sprague Dawley rats resulted in sustained prodrug levels in blood, liver, spleen and lymph nodes and FTC-TP in lymph node and spleen cells at one month. In contrast, native FTC-TPs was present for one day. These results are an advance in the transformation of FTC into a LA agent.
Collapse
Affiliation(s)
- Dhruvkumar Soni
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Aditya N Bade
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Nagsen Gautam
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Jonathan Herskovitz
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Ibrahim M Ibrahim
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Nathan Smith
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Melinda S Wojtkiewicz
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Bhagya Laxmi Dyavar Shetty
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Yazen Alnouti
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - JoEllyn McMillan
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Howard E Gendelman
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
| | - Benson J Edagwa
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
| |
Collapse
|
109
|
Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds. JOURNAL OF DRUG DELIVERY 2019; 2019:1957360. [PMID: 31360551 PMCID: PMC6644232 DOI: 10.1155/2019/1957360] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 05/20/2019] [Accepted: 06/25/2019] [Indexed: 02/08/2023]
Abstract
Despite recent advances, the drug development process continues to face significant challenges to efficiently improve the poor solubility of active pharmaceutical ingredients (API) in aqueous media or to improve the bioavailability of lipid-based formulations. The inherent high intra- and interindividual variability of absorption of oral lipophilic drug leads to inconsistent and unpredictable bioavailability and magnitude of the therapeutic effect. For this reason, the development of lipid-based drugs remains a challenging endeavour with a high risk of failure. Therefore, effective strategies to assure a predictable, consistent, and reproducible bioavailability and therapeutic effect for lipid-based medications are needed. Different solutions to address this problem have been broadly studied, including the approaches of particle size reduction, prodrugs, salt forms, cocrystals, solid amorphous forms, cyclodextrin clathrates, and lipid-based drug delivery systems such as self-emulsifying systems and liposomes. Here, we provide a brief description of the current strategies commonly employed to increase the bioavailability of lipophilic drugs and present Advanced Lipid Technologies® (ALT®), a combination of different surfactants that has been demonstrated to improve the absorption of omega-3 fatty acids under various physiological and pathological states.
Collapse
|
110
|
Su M, Qiu L, Deng Y, Ruiz CH, Rudolf JD, Dong LB, Feng X, Cameron MD, Shen B, Duan Y, Huang Y. Evaluation of Platensimycin and Platensimycin-Inspired Thioether Analogues against Methicillin-Resistant Staphylococcus aureus in Topical and Systemic Infection Mouse Models. Mol Pharm 2019; 16:3065-3071. [PMID: 31244223 PMCID: PMC6763203 DOI: 10.1021/acs.molpharmaceut.9b00293] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Staphylococcus aureus is one of the most common pathogens causing hospital-acquired and community-acquired infections. Methicillin-resistant S. aureus (MRSA)-formed biofilms in wounds are difficult to treat with conventional antibiotics. By targeting FabB/FabF of bacterial fatty acid synthases, platensimycin (PTM) was discovered to act as a promising natural antibiotic against MRSA infections. In this study, PTM and its previously synthesized sulfur-Michael derivative PTM-2t could reduce over 95% biofilm formation by S. aureus ATCC 29213 when used at 2 μg/mL in vitro. Topical application of ointments containing PTM or PTM-2t (2 × 4 mg/day/mouse) was successfully used to treat MRSA infections in a BABL/c mouse burn wound model. As a potential prodrug lead, PTM-2t showed improved in vivo efficacy in a mouse peritonitis model compared with PTM. Our study suggests that PTM and its analogue may be used topically or locally to treat bacterial infections. In addition, the use of prodrug strategies might be instrumental to improve the poor pharmacokinetic properties of PTM.
Collapse
Affiliation(s)
- Meng Su
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
| | - Lin Qiu
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
| | - Youchao Deng
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
| | - Claudia H. Ruiz
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Jeffrey D. Rudolf
- Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Liao-Bin Dong
- Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Xueqiong Feng
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
| | - Michael D. Cameron
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Ben Shen
- Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
- Department of Natural Products Library Initiative at The Scripps Research Institute, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Yanwen Duan
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
- Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery, Changsha, Hunan 410011, China
- National Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery, Changsha, Hunan 410011, China
| | - Yong Huang
- Xiangya International Academy of Translational Medicine at Central South University, Changsha, Hunan 410013, China
- National Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery, Changsha, Hunan 410011, China
| |
Collapse
|
111
|
Weir SJ, Wood R, Schorno K, Brinker AE, Ramamoorthy P, Heppert K, Rajewski L, Tanol M, Ham T, McKenna MJ, McCulloch W, Dalton M, Reed GA, Jensen RA, Baltezor MJ, Anant S, Taylor JA. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther 2019; 370:148-159. [PMID: 31113837 DOI: 10.1124/jpet.119.257972] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Accepted: 05/08/2019] [Indexed: 12/20/2022] Open
Abstract
Pharmacokinetic studies in rats and dogs were performed to characterize the in vivo performance of a novel prodrug, fosciclopirox. Ciclopirox olamine (CPX-O) is a marketed topical antifungal agent with demonstrated in vitro and in vivo preclinical anticancer activity in several solid tumor and hematologic malignancies. The oral route of administration for CPX-O is not feasible due to low bioavailability and dose-limiting gastrointestinal toxicities. To enable parenteral administration, the phosphoryl-oxymethyl ester of ciclopirox (CPX), fosciclopirox (CPX-POM), was synthesized and formulated as an injectable drug product. In rats and dogs, intravenous CPX-POM is rapidly and completely metabolized to its active metabolite, CPX. The bioavailability of the active metabolite is complete following CPX-POM administration. CPX and its inactive metabolite, ciclopirox glucuronide (CPX-G), are excreted in urine, resulting in delivery of drug to the entire urinary tract. The absolute bioavailability of CPX following subcutaneous administration of CPX-POM is excellent in rats and dogs, demonstrating the feasibility of this route of administration. These studies confirmed the oral bioavailability of CPX-O is quite low in rats and dogs compared with intravenous CPX-POM. Given its broad-spectrum anticancer activity in several solid tumor and hematologic cancers and renal elimination, CPX-POM is being developed for the treatment of urothelial cancer. The safety, dose tolerance, pharmacokinetics, and pharmacodynamics of intravenous CPX-POM are currently being characterized in a United States multicenter first-in-human Phase 1 clinical trial in patients with advanced solid tumors (NCT03348514).
Collapse
Affiliation(s)
- Scott J Weir
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Robyn Wood
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Karl Schorno
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Amanda E Brinker
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Prabhu Ramamoorthy
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Kathy Heppert
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Lian Rajewski
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Mehmet Tanol
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Tammy Ham
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Michael J McKenna
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - William McCulloch
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Michael Dalton
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Gregory A Reed
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Roy A Jensen
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Michael J Baltezor
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - Shrikant Anant
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| | - John A Taylor
- University of Kansas Cancer Center, Kansas City, Kansas (S.J.W., R.W., A.E.B., G.A.R., R.A.J., M.J.B., S.A., J.A.T.); Institute for Advancing Medical Innovation (S.J.W., R.W., A.E.B., M.J.B.) and Departments of Cancer Biology (S.J.W., P.R., S.A.), Pharmacology, Toxicology, and Therapeutics (S.J.W., G.A.R.) Pathology (R.A.J.), and Urology (J.A.T.), University of Kansas Medical Center, Kansas City, Kansas; Biotechnology Innovation and Optimization Center, University of Kansas, Lawrence, Kansas (K.S., K.H., L.R., M.T., M.J.B.); School of Pharmacy, Istanbul Kemerburgaz University, Istanbul, Turkey (M.T.); CicloMed LLC, Kansas City, Missouri (T.H.); Navigator LSA, Wilmington, North Carolina (M.J.M.); Alba BioPharm Advisors Inc., Durham, North Carolina (W.M.); and The Gnomon Group, Carrboro, North Carolina (M.D.)
| |
Collapse
|
112
|
Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs. Int J Mol Sci 2019; 20:ijms20092210. [PMID: 31060339 PMCID: PMC6538990 DOI: 10.3390/ijms20092210] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 04/29/2019] [Accepted: 05/01/2019] [Indexed: 02/06/2023] Open
Abstract
The lipidic prodrug approach is an emerging field for improving a number of biopharmaceutical and drug delivery aspects. Owing to their structure and nature, phospholipid (PL)-based prodrugs may join endogenous lipid processing pathways, and hence significantly improve the pharmacokinetics and/or bioavailability of the drug. Additional advantages of this approach include drug targeting by enzyme-triggered drug release, blood–brain barrier permeability, lymphatic targeting, overcoming drug resistance, or enabling appropriate formulation. The PL-prodrug design includes various structural modalities-different conjugation strategies and/or the use of linkers between the PL and the drug moiety, which considerably influence the prodrug characteristics and the consequent effects. In this article, we describe how molecular modeling can guide the structural design of PL-based prodrugs. Computational simulations can predict the extent of phospholipase A2 (PLA2)-mediated activation, and facilitate prodrug development. Several computational methods have been used to facilitate the design of the pro-drugs, which will be reviewed here, including molecular docking, the free energy perturbation method, molecular dynamics simulations, and free density functional theory. Altogether, the studies described in this article indicate that computational simulation-guided PL-based prodrug molecular design correlates well with the experimental results, allowing for more mechanistic and less empirical development. In the future, the use of molecular modeling techniques to predict the activity of PL-prodrugs should be used earlier in the development process.
Collapse
Affiliation(s)
- Milica Markovic
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| | - Shimon Ben-Shabat
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| | | | - Aaron Aponick
- Department of Chemistry, University of Florida, Gainesville, FL 32603, USA.
| | - Ellen M Zimmermann
- Department of Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL 32608, USA.
| | - Arik Dahan
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| |
Collapse
|
113
|
Nonoyama A, Nakai Y, Lee S, Suzuki S, Ando T, Fukuda N, Tanaka H, Takahashi K. Process Development of an Efficient and Cost-Effective Telescoping Route to a Key Synthetic Precursor for the Preparation of a Renin Inhibitor. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.8b00414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Akihito Nonoyama
- Process Chemistry Research and Development Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Yoshio Nakai
- Chemistry Research Unit Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Shoukou Lee
- Chemistry Research Unit Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Satoshi Suzuki
- Formulation Research and Development Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 13-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8356, Japan
| | - Takeya Ando
- Process Chemistry Research and Development Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Nobuhisa Fukuda
- Chemistry Research Unit Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Hiroaki Tanaka
- Process Chemistry Research and Development Laboratories, Sumitomo Dainippon Pharma Co., Ltd., 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | - Kazuhiko Takahashi
- Technology Research and Development Division, Sumitomo Dainippon Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka 564-0053, Japan
| |
Collapse
|
114
|
Choi Y, Min KA, Kim CK. Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect. Drug Dev Ind Pharm 2019; 45:895-904. [DOI: 10.1080/03639045.2019.1576720] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Yoonho Choi
- College of Pharmacy, Seoul National University, Seoul, Republic of Korea
| | - Kyoung Ah Min
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Republic of Korea
| | - Chong-Kook Kim
- College of Pharmacy, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
115
|
Abdou MM, O'Neill PM, Amigues E, Matziari M. Phosphinic acids: current status and potential for drug discovery. Drug Discov Today 2019; 24:916-929. [PMID: 30481556 DOI: 10.1016/j.drudis.2018.11.016] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 11/05/2018] [Accepted: 11/20/2018] [Indexed: 01/17/2023]
Abstract
Phosphinic acid derivatives exhibit diverse biological activities and a high degree of structural diversity, rendering them a versatile tool in the development of new medicinal agents. Pronounced recent progress, coupled with previous research findings, highlights the impact of this moiety in medicinal chemistry. Here, we highlight the most important breakthroughs made with phosphinates with a range of pharmacological activities against many diseases, including anti-inflammatory, anti-Alzheimer, antiparasitic, antihepatitis, antiproliferative, anti-influenza, anti-HIV, antimalarial, and antimicrobial agents. We also provide the current status of the corresponding prodrugs, drug-delivery systems, and drug applications of phosphinic acids in the clinical stage.
Collapse
Affiliation(s)
- Moaz M Abdou
- Egyptian Petroleum Research Institute, Nasr City, PO 11727, Cairo, Egypt; Department of Chemistry, Xi'an Jiaotong Liverpool University, Suzhou, Jiangsu 215123, PR China; Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, UK
| | - Paul M O'Neill
- Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, UK; Department of Pharmacology, School of Biomedical Sciences, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, UK
| | - Eric Amigues
- Department of Chemistry, Xi'an Jiaotong Liverpool University, Suzhou, Jiangsu 215123, PR China
| | - Magdalini Matziari
- Department of Chemistry, Xi'an Jiaotong Liverpool University, Suzhou, Jiangsu 215123, PR China.
| |
Collapse
|
116
|
Tung YC, Chou YC, Hung WL, Cheng AC, Yu RC, Ho CT, Pan MH. Polymethoxyflavones: Chemistry and Molecular Mechanisms for Cancer Prevention and Treatment. ACTA ACUST UNITED AC 2019. [DOI: 10.1007/s40495-019-00170-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
117
|
Tao J, Chow SF, Zheng Y. Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles. Acta Pharm Sin B 2019; 9:4-18. [PMID: 30766774 PMCID: PMC6361851 DOI: 10.1016/j.apsb.2018.11.001] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 11/02/2018] [Accepted: 11/04/2018] [Indexed: 01/08/2023] Open
Abstract
Nanoparticles are considered to be a powerful approach for the delivery of poorly water-soluble drugs. One of the main challenges is developing an appropriate method for preparation of drug nanoparticles. As a simple, rapid and scalable method, the flash nanoprecipitation (FNP) has been widely used to fabricate these drug nanoparticles, including pure drug nanocrystals, polymeric micelles, polymeric nanoparticles, solid lipid nanoparticles, and polyelectrolyte complexes. This review introduces the application of FNP to produce poorly water-soluble drug nanoparticles by controllable mixing devices, such as confined impinging jets mixer (CIJM), multi-inlet vortex mixer (MIVM) and many other microfluidic mixer systems. The formation mechanisms and processes of drug nanoparticles by FNP are described in detail. Then, the controlling of supersaturation level and mixing rate during the FNP process to tailor the ultrafine drug nanoparticles as well as the influence of drugs, solvent, anti-solvent, stabilizers and temperature on the fabrication are discussed. The ultrafine and uniform nanoparticles of poorly water-soluble drug nanoparticles prepared by CIJM, MIVM and microfluidic mixer systems are reviewed briefly. We believe that the application of microfluidic mixing devices in laboratory with continuous process control and good reproducibility will be benefit for industrial formulation scale-up.
Collapse
Key Words
- ACN, acetonitrile
- CA 320S Seb, cellulose acetate 320S sebacate
- CAP Adp 0.33, cellulose acetate propionate 504-0.2 adipate 0.33
- CAP Adp 0.85, cellulose acetate propionate adipate 0.85
- CFA, cefuroxime axetil
- CIJM, confined impinging jets mixer
- CMCAB, carboxymethyl cellulose acetate butyrate
- CTACl, cetyltrimethylammonium chloride
- DMF, dimethyl formamide
- DMSO, dimethyl sulfoxide
- DSPE-PEG, distearyl phosphatidyl ethanolamine-poly(ethylene glycol)
- Dex-PLLA, dextrose-poly(l-lactic acid)
- FNP, flash nanoprecipitation
- Flash nanoprecipitation
- HPC, hydroxypropyl cellulose
- HPMC, hydroxypropyl methyl cellulose
- HPMCAS, hydroxypropyl methylcellulose acetate succinate
- MIVM, multi-inlet vortex mixer
- Microfluidic mixer device
- NaAlg, sodium alginate
- NaCMC, carboxymethyl cellulose sodium
- Nanoparticles
- P(MePEGCA-co-HDCA), poly(methoxy polyethylene glycol cyanoacrylate-co-hexadecyl cyanoacrylate)
- PAA, poly(acrylic acid)
- PAH, polyallylamine hydrochloride
- PCL, poly(ε-caprolactone)
- PEG, polyethylene glycol
- PEG-PCL, poly(ethylene glycol)-poly(ε-caprolactone)
- PEG-PLA, poly(ethylene glycol)-poly(lactic acid)
- PEG-PLGA, poly(ethylene glycol)-poly(lactic-co-glycolic acid)
- PEG-PS, poly(ethylene glycol)-polystyrene
- PEI, polyethyleneimine
- PEO-PDLLA, poly(ethylene oxide)-poly(d,l-lactic acid)
- PLA, poly(lactic acid)
- PLGA, poly(lactic-co-glycolic acid)
- PMMA, polymethyl methacrylate
- PSS, polyprotomine sulfate
- PVA, polyvinyl alcohol
- PVP, polyvinyl pyrrolidone
- Poorly water-soluble drug
- SDS, sodium dodecyl sulfonate
- SLS, sodium lauryl sulfate
- THF, tetrahydrofuran
- TPGS, tocopheryl polyethylene glycol 1000 succinate
- ε-PL, ε-polylysine
Collapse
Affiliation(s)
- Jinsong Tao
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Science, University of Macau, Macau, China
| | - Shing Fung Chow
- Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China
| | - Ying Zheng
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Science, University of Macau, Macau, China
| |
Collapse
|
118
|
Goethe O, Heuer A, Ma X, Wang Z, Herzon SB. Antibacterial properties and clinical potential of pleuromutilins. Nat Prod Rep 2019; 36:220-247. [PMID: 29979463 DOI: 10.1039/c8np00042e] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Covering: up to 2018Pleuromutilins are a clinically validated class of antibiotics derived from the fungal diterpene (+)-pleuromutilin (1). Pleuromutilins inhibit bacterial protein synthesis by binding to the peptidyl transferase center (PTC) of the ribosome. In this review we summarize the biosynthesis and recent total syntheses of (+)-pleuromutilin (1). We review the mode of interaction of pleuromutilins with the bacterial ribosome, which involves binding of the C14 extension and the tricyclic core to the P and A sites of the PTC, respectively. We provide an overview of existing clinical agents, and discuss the three primary modes of bacterial resistance (mutations in ribosomal protein L3, Cfr methylation, and efflux). Finally we collect structure-activity relationships from publicly available reports, and close with some forward looking statements regarding future development.
Collapse
Affiliation(s)
- Olivia Goethe
- Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA.
| | - Abigail Heuer
- Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA.
| | - Xiaoshen Ma
- Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA.
| | - Zhixun Wang
- Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA.
| | - Seth B Herzon
- Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA. and Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut 06520, USA
| |
Collapse
|
119
|
Kopec BM, Ulapane KR, Moral MEG, Siahaan TJ. Methods of Delivering Molecules Through the Blood-Brain Barrier for Brain Diagnostics and Therapeutics. BLOOD-BRAIN BARRIER 2019. [DOI: 10.1007/978-1-4939-8946-1_2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
120
|
Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Prospects and Challenges of Phospholipid-Based Prodrugs. Pharmaceutics 2018; 10:pharmaceutics10040210. [PMID: 30388756 PMCID: PMC6321354 DOI: 10.3390/pharmaceutics10040210] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 10/24/2018] [Accepted: 10/26/2018] [Indexed: 12/19/2022] Open
Abstract
Nowadays, the prodrug approach is used already at the early stages of drug development. Lipidic prodrug approach is a growing field for improving a number of drug properties/delivery/therapy aspects, and can offer solutions for various unmet needs. This approach includes drug moiety bound to the lipid carrier, which can be triglyceride, fatty acids, steroid, or phospholipid (PL). The focus of this article is PL-based prodrugs, which includes a PL carrier covalently bound to the active drug moiety. An overview of relevant physiological lipid processing pathways and absorption barriers is provided, followed by drug delivery/therapeutic application of PL-drug conjugates, as well as computational modeling techniques, and a modern bioinformatics tool that can aid in the optimization of PL conjugates. PL-based prodrugs have increased lipophilicity comparing to the parent drug, and can therefore significantly improve the pharmacokinetic profile and overall bioavailability of the parent drug, join the endogenous lipid processing pathways and therefore accomplish drug targeting, e.g., by lymphatic transport, drug release at specific target site(s), or passing the blood-brain barrier. Moreover, an exciting gateway for treating inflammatory diseases and cancer is presented, by utilizing the PL sn-2 position in the prodrug design, aiming for PLA₂-mediated activation. Overall, a PL-based prodrug approach shows great potential in improving different drug delivery/therapy aspects, and is expected to grow.
Collapse
Affiliation(s)
- Milica Markovic
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| | - Shimon Ben-Shabat
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| | | | - Aaron Aponick
- Department of Chemistry, University of Florida, Gainesville, FL 32603, USA.
| | - Ellen M Zimmermann
- Department of Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL 32610, USA.
| | - Arik Dahan
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| |
Collapse
|
121
|
Markovic M, Ben‐Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Lipidic prodrug approach for improved oral drug delivery and therapy. Med Res Rev 2018; 39:579-607. [DOI: 10.1002/med.21533] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 07/26/2018] [Accepted: 07/27/2018] [Indexed: 12/13/2022]
Affiliation(s)
- Milica Markovic
- Department of Clinical PharmacologySchool of Pharmacy, Faculty of Health Sciences, Ben‐Gurion University of the NegevBeer‐Sheva Israel
| | - Shimon Ben‐Shabat
- Department of Clinical PharmacologySchool of Pharmacy, Faculty of Health Sciences, Ben‐Gurion University of the NegevBeer‐Sheva Israel
| | | | - Aaron Aponick
- Department of ChemistryUniversity of FloridaGainesville Florida
| | - Ellen M. Zimmermann
- Department of MedicineDivision of Gastroenterology, University of FloridaGainesville Florida
| | - Arik Dahan
- Department of Clinical PharmacologySchool of Pharmacy, Faculty of Health Sciences, Ben‐Gurion University of the NegevBeer‐Sheva Israel
| |
Collapse
|
122
|
Kumar Sahoo S, Sankar Dash G, Biswal S, Kumar Biswal P, Chandra Senapati P. Fabrication and evaluation of self-nanoemulsifying oil formulations (SNEOFs) of Efavirenz. J DISPER SCI TECHNOL 2018. [DOI: 10.1080/01932691.2018.1472008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Sunit Kumar Sahoo
- University Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha, India
| | - Gyanada Sankar Dash
- Department of Pharmaceutics, Sri Jayadev College of Pharmaceutical Sciences,Bhubaneswar, Odisha, India
| | - Satyajeet Biswal
- University Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha, India
| | | | - Prakash Chandra Senapati
- Department of Pharmaceutics, Sri Jayadev College of Pharmaceutical Sciences,Bhubaneswar, Odisha, India
| |
Collapse
|
123
|
Ho DK, Frisch S, Biehl A, Terriac E, De Rossi C, Schwarzkopf K, Lautenschläger F, Loretz B, Murgia X, Lehr CM. Farnesylated Glycol Chitosan as a Platform for Drug Delivery: Synthesis, Characterization, and Investigation of Mucus–Particle Interactions. Biomacromolecules 2018; 19:3489-3501. [DOI: 10.1021/acs.biomac.8b00795] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Duy-Khiet Ho
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | - Sarah Frisch
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | - Alexander Biehl
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | | | - Chiara De Rossi
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | - Konrad Schwarzkopf
- Department of Anesthesia and Intensive Care, Klinikum Saarbrücken, 66119 Saarbrücken, Germany
| | | | - Brigitta Loretz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | - Xabier Murgia
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| | - Claus-Michael Lehr
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), ‡Department of Pharmacy, §INM−Leibniz Institute for New Materials, and ⊥Korea Institute of Science and Technology, KIST Europe, Saarland University, D-66123 Saarbrücken, Germany
| |
Collapse
|
124
|
Chae S, Kim D, Lee KJ, Lee D, Kim YO, Jung YC, Rhee SD, Kim KR, Lee JO, Ahn S, Koh B. Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes. ACS OMEGA 2018; 3:5938-5945. [PMID: 30023933 PMCID: PMC6044808 DOI: 10.1021/acsomega.8b00399] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 05/22/2018] [Indexed: 05/04/2023]
Abstract
The topoisomerase I inhibitors SN-38 and camptothecin (CPT) have shown potent anticancer activity, but water insolubility and metabolic instability limits their clinical application. Utilizing carbon nanotubes as a protective shell for water-insoluble SN-38 and CPT while maintaining compatibility with aqueous media via a carboxylic acid-functionalized surface can thus be a strategy to overcome this limitation. Through hydrophobic-hydrophobic interactions, SN-38 and CPT were successfully encapsulated in carboxylic acid functionalized single-walled carbon nanotubes and dispersed in water. The resulting cell proliferation inhibition and drug distribution profile inside the cells suggest that these drug-encapsulated carbon nanotubes can serve as a promising delivery strategy for water-insoluble anticancer drugs.
Collapse
Affiliation(s)
- Sieun Chae
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Dahee Kim
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Kyung-jin Lee
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Dasol Lee
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Young-O Kim
- Institute
of Advanced Composite Materials, Korea Institute
of Science and Technology, 92 Chudong-ro, Bongdong-eup, Wanju-gun, Jeollabuk-do 55324, Republic of Korea
| | - Yong Chae Jung
- Institute
of Advanced Composite Materials, Korea Institute
of Science and Technology, 92 Chudong-ro, Bongdong-eup, Wanju-gun, Jeollabuk-do 55324, Republic of Korea
| | - Sang Dal Rhee
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Kwang Rok Kim
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Jeong-O Lee
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Sunjoo Ahn
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| | - Byumseok Koh
- Advanced
Materials Division and Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro,
Yuseong-gu, Daejeon 34114, Republic of Korea
| |
Collapse
|
125
|
Okoh OA, Klahn P. Trimethyl Lock: A Multifunctional Molecular Tool for Drug Delivery, Cellular Imaging, and Stimuli-Responsive Materials. Chembiochem 2018; 19:1668-1694. [PMID: 29888433 DOI: 10.1002/cbic.201800269] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Indexed: 12/13/2022]
Abstract
Trimethyl lock (TML) systems are based on ortho-hydroxydihydrocinnamic acid derivatives displaying increased lactonization reactivity owing to unfavorable steric interactions of three pendant methyl groups, and this leads to the formation of hydrocoumarins. Protection of the phenolic hydroxy function or masking of the reactivity as benzoquinone derivatives prevents lactonization and provides a trigger for controlled release of molecules attached to the carboxylic acid function through amides, esters, or thioesters. Their easy synthesis and possible chemical adaption to several different triggers make TML a highly versatile module for the development of drug-delivery systems, prodrug approaches, cell-imaging tools, molecular tools for supramolecular chemistry, as well as smart stimuliresponsive materials.
Collapse
Affiliation(s)
- Okoh Adeyi Okoh
- Institute for Organic Chemistry, Technische Universität Braunschweig, Hagenring 30, 38106, Braunschweig, Germany
| | - Philipp Klahn
- Institute for Organic Chemistry, Technische Universität Braunschweig, Hagenring 30, 38106, Braunschweig, Germany
| |
Collapse
|
126
|
Discovery, identification and mitigation of isobaric sulfate metabolite interference to a phosphate prodrug in LC–MS/MS bioanalysis: Critical role of method development in ensuring assay quality. J Pharm Biomed Anal 2018; 155:141-147. [DOI: 10.1016/j.jpba.2018.03.064] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 03/27/2018] [Accepted: 03/30/2018] [Indexed: 11/19/2022]
|
127
|
Li Y, Yang H, Yao J, Yu H, Chen X, Zhang P, Xiao C. Glutathione-triggered dual release of doxorubicin and camptothecin for highly efficient synergistic anticancer therapy. Colloids Surf B Biointerfaces 2018; 169:273-279. [PMID: 29787951 DOI: 10.1016/j.colsurfb.2018.05.025] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 05/10/2018] [Accepted: 05/11/2018] [Indexed: 12/30/2022]
Abstract
An amphiphilic biodegradable prodrug (PLG-g-mPEG/CPT) was synthesized by conjugating disulfide-containing camptothecin (CPT) to poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) (PLG-g-mPEG) through esterification reaction. The amphiphilic prodrugs could self-assemble into micellar nanoparticles and encapsulate doxorubicin (DOX) in aqueous solution at pH 7.4. The treatment of the nanoparticles with reducing glutathione (GSH) at cytosolic concentration (10 mM) significantly promoted the in vitro dual release of DOX and CPT from the micelles. The results of flow cytometry (FCM) and confocal laser scanning microscopy (CLSM) manifested that the intracellular release of DOX and CPT from the micelles was enhanced by increasing the intracellular GSH level. Consistently, the MCF-7 cell killing mediated by the micelles was also intracellular GSH concentration-dependent. The low combination index (CI) value of < 0.3 demonstrated the high synergistic effect of DOX and CPT co-delivered by the nanoparticles in tumor cell killing. Therefore, this GSH-triggered dual release drug delivery system is a promising strategy for combination cancer therapy.
Collapse
Affiliation(s)
- Yiwen Li
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China
| | - Huailin Yang
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China; Department of Chemistry, Northeast Normal University, Changchun 130022, PR China
| | - Jiuxu Yao
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China; Department of Chemistry, Northeast Normal University, Changchun 130022, PR China
| | - Haiyang Yu
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China
| | - Xin Chen
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China; University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing 100049, PR China
| | - Peng Zhang
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
| | - Chunsheng Xiao
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
| |
Collapse
|
128
|
Meise M, Niggemann M, Dunens A, Schoenitz M, Kuschnerow JC, Kunick C, Scholl S. Early process development of API applied to poorly water-soluble TBID. Eur J Pharm Biopharm 2018; 126:2-9. [DOI: 10.1016/j.ejpb.2018.01.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Revised: 11/28/2017] [Accepted: 01/11/2018] [Indexed: 12/25/2022]
|
129
|
Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018; 17:559-587. [DOI: 10.1038/nrd.2018.46] [Citation(s) in RCA: 325] [Impact Index Per Article: 54.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
130
|
Ho DK, Costa A, De Rossi C, de Souza Carvalho-Wodarz C, Loretz B, Lehr CM. Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake. Mol Pharm 2018; 15:1081-1096. [PMID: 29425049 DOI: 10.1021/acs.molpharmaceut.7b00967] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The majority of the currently used and developed anti-infectives are poorly water-soluble molecules. The poor solubility might lead to limited bioavailability and pharmacological action of the drug. Novel pharmaceutical materials have thus been designed to solve those problems and improve drug delivery. In this study, we propose a facile method to produce submicrocarriers (sMCs) by electrostatic gelation of anionic ß-cyclodextrin (aß-CD) and chitosan. The average hydrodynamic size ranged from 400 to 900 nm by carefully adjusting polymer concentrations and N/C ratio. The distinct host-guest reaction of cyclodextrin derivative is considered as a good approach to enhance solubility, and prevent drug recrystallization, and thus was used to develop sMC to improve the controlled release profile of a poorly soluble and clinically relevant anti-infective ciprofloxacin. The optimal molar ratio of ciprofloxacin to aß-CD was found to be 1:1, which helped maximize encapsulation efficiency (∼90%) and loading capacity (∼9%) of ciprofloxacin loaded sMCs. Furthermore, to recommend the future application of the developed sMCs, the dependence of cell uptake on sMCs size (500, 700, and 900 nm) was investigated in vitro on dTHP-1 by both flow cytometry and confocal microscopy. The results demonstrate that, regardless of their size, an only comparatively small fraction of the sMCs were taken up by the macrophage-like cells, while most of the carriers were merely adsorbed to the cell surface after 2 h incubation. After continuing the incubation to reach 24 h, the majority of the sMCs were found intracellularly. However, the sMCs had been designed to release sufficient amount of drug within 24 h, and the subsequent phagocytosis of the carrier may be considered as an efficient pathway for its safe degradation and elimination. In summary, the developed sMC is a suitable system with promising perspectives recommended for pulmonary extracellular infection therapeutics.
Collapse
Affiliation(s)
- Duy-Khiet Ho
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University , D-66123 Saarbrücken , Germany.,Department of Pharmacy , Saarland University , D-66123 Saarbrücken , Germany
| | - Ana Costa
- I3S, Instituto de Investigação e Inovação em Saúde Universidade do Porto , 4200-135 Porto , Portugal.,Instituto Nacional de Engenharia Biomédica (INEB), Universidade do Porto , 4200-135 Porto , Portugal.,Instituto Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto , 4050-313 Porto , Portugal
| | - Chiara De Rossi
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University , D-66123 Saarbrücken , Germany
| | - Cristiane de Souza Carvalho-Wodarz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University , D-66123 Saarbrücken , Germany
| | - Brigitta Loretz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University , D-66123 Saarbrücken , Germany
| | - Claus-Michael Lehr
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University , D-66123 Saarbrücken , Germany.,Department of Pharmacy , Saarland University , D-66123 Saarbrücken , Germany
| |
Collapse
|
131
|
Fan N, He Z, Ma P, Wang X, Li C, Sun J, Sun Y, Li J. Impact of HPMC on inhibiting crystallization and improving permeability of curcumin amorphous solid dispersions. Carbohydr Polym 2018; 181:543-550. [DOI: 10.1016/j.carbpol.2017.12.004] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 10/22/2017] [Accepted: 12/04/2017] [Indexed: 01/30/2023]
|
132
|
Du W, Hu X, Wei W, Liang G. Intracellular Peptide Self-Assembly: A Biomimetic Approach for in Situ Nanodrug Preparation. Bioconjug Chem 2018; 29:826-837. [PMID: 29316785 DOI: 10.1021/acs.bioconjchem.7b00798] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Most nanodrugs are preprepared by encapsulating or loading the drugs with nanocarriers (e.g., dendrimers, liposomes, micelles, and polymeric nanoparticles). However, besides the low bioavailability and fast excretion of the nanodrugs in vivo, nanocarriers often exhibit in vitro and in vivo cytotoxicity, oxidative stress, and inflammation. Self-assembly is a ubiquitous process in biology where it plays important roles and underlies the formation of a wide variety of complex biological structures. Inspired by some cellular nanostructures (e.g., actin filaments, microtubules, vesicles, and micelles) in biological systems which are formed via molecular self-assembly, in recent decades, scientists have utilized self-assembly of oligomeric peptide under specific physiological or pathological environments to in situ construct nanodrugs for lesion-targeted therapies. On one hand, peptide-based nanodrugs always have some excellent intrinsic chemical (specificity, intrinsic bioactivity, biodegradability) and physical (small size, conformation) properties. On the other hand, stimuli-regulated intracellular self-assembly of nanodrugs is quite an efficient way to accumulate the drugs in lesion location and can realize an in situ slow release of the drugs. In this review article, we provided an overview on recent design principles for intracellular peptide self-assembly and illustrate how these principles have been applied for the in situ preparation of nanodrugs at the lesion location. In the last part, we list some challenges underlying this strategy and their possible solutions. Moreover, we envision the future possible theranostic applications of this strategy.
Collapse
Affiliation(s)
- Wei Du
- CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry , University of Science and Technology of China , 96 Jinzhai Road , Hefei , Anhui 230026 , China
| | - Xiaomu Hu
- Department of Medicinal Chemistry, School of Pharmacy , The Fourth Military Medical University , Changle West Road 169 , Xi'an , Shanxi 710032 , China
| | - Weichen Wei
- CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry , University of Science and Technology of China , 96 Jinzhai Road , Hefei , Anhui 230026 , China
| | - Gaolin Liang
- CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry , University of Science and Technology of China , 96 Jinzhai Road , Hefei , Anhui 230026 , China
| |
Collapse
|
133
|
Wu J, Chen Y, Liu X, Gao Y, Hu J, Chen H. Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia. Chem Biol Drug Des 2018; 91:924-932. [PMID: 29240303 DOI: 10.1111/cbdd.13159] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 10/03/2017] [Accepted: 12/01/2017] [Indexed: 12/26/2022]
Abstract
Baicalin and its aglycone baicalein derived from Scutellaria baicalensis exhibited potent anticancer effects in various types of cancer cell lines. However, the unfavorable pharmaceutical properties became the main obstacle for their potential clinical development. With the aim of development of novel anticancer agents based on the skeleton of baicalin, a series of novel negletein derivatives were designed and synthesized. Among them, compound 8 (FZU-02,006) with an N,N-dimethylamino ethoxyl moiety at the C-6 position exhibited significant enhanced antiproliferative effect against HL-60 cells in vitro through regulating multisignaling pathways. These results revealed that compound 8 with the improved aqueous solubility (as HCl salt, >1 mg/ml) and enhanced antileukemia potency might serve as a promising lead for further development.
Collapse
Affiliation(s)
- Jianlei Wu
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, China
| | - Yingyu Chen
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Xuanping Liu
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, China
| | - Yu Gao
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, China
| | - Jianda Hu
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Haijun Chen
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, China
| |
Collapse
|
134
|
Ting JM, Porter WW, Mecca JM, Bates FS, Reineke TM. Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery. Bioconjug Chem 2018; 29:939-952. [PMID: 29319295 DOI: 10.1021/acs.bioconjchem.7b00646] [Citation(s) in RCA: 87] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Synthetic polymers have enabled amorphous solid dispersions (ASDs) to emerge as an oral delivery strategy for overcoming poor drug solubility in aqueous environments. Modern ASD products noninvasively treat a range of chronic diseases (for example, hepatitis C, cystic fibrosis, and HIV). In such formulations, polymeric carriers generate and maintain drug supersaturation upon dissolution, increasing the apparent drug solubility to enhance gastrointestinal barrier absorption and oral bioavailability. In this Review, we outline several approaches in designing polymeric excipients to drive interactions with active pharmaceutical ingredients (APIs) in spray-dried ASDs, highlighting polymer-drug formulation guidelines from industrial and academic perspectives. Special attention is given to new commercial and specialized polymer design strategies that can solubilize highly hydrophobic APIs and suppress the propensity for rapid drug recrystallization. These molecularly customized excipients and hierarchical excipient assemblies are promising toward informing early-stage drug-discovery development and reformulating existing API candidates into potentially lifesaving oral medicines for our growing global population.
Collapse
|
135
|
Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2017; 38:1295-1331. [PMID: 29149530 DOI: 10.1002/med.21475] [Citation(s) in RCA: 107] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 09/10/2017] [Accepted: 10/17/2017] [Indexed: 12/31/2022]
Abstract
There are numerous proteases of pathogenic organisms that are currently targeted for therapeutic intervention along with many that are seen as potential drug targets. This review discusses the chemical and biological makeup of some key druggable proteases expressed by the five major classes of disease causing agents, namely bacteria, viruses, fungi, eukaryotes, and prions. While a few of these enzymes including HIV protease and HCV NS3-4A protease have been targeted to a clinically useful level, a number are yet to yield any clinical outcomes in terms of antimicrobial therapy. A significant aspect of this review discusses the chemical and pharmacological characteristics of inhibitors of the various proteases discussed. A total of 25 inhibitors have been considered potent and safe enough to be trialed in humans and are at different levels of clinical application. We assess the mechanism of action and clinical performance of the protease inhibitors against infectious agents with their developmental strategies and look to the next frontiers in the use of protease inhibitors as anti-infective agents.
Collapse
Affiliation(s)
| | - Wilhelmina M Huston
- School of Life Sciences, University of Technology Sydney, Ultimo, NSW, Australia
| | - Allan B Gamble
- School of Pharmacy, University of Otago, Dunedin, New Zealand
| | | |
Collapse
|
136
|
Luckanagul JA, Pitakchatwong C, Ratnatilaka Na Bhuket P, Muangnoi C, Rojsitthisak P, Chirachanchai S, Wang Q, Rojsitthisak P. Chitosan-based polymer hybrids for thermo-responsive nanogel delivery of curcumin. Carbohydr Polym 2017; 181:1119-1127. [PMID: 29253940 DOI: 10.1016/j.carbpol.2017.11.027] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Revised: 08/17/2017] [Accepted: 11/07/2017] [Indexed: 11/16/2022]
Abstract
The purpose of this study is to design and develop thermoresponsive nano-sized hydrogel particles from a natural polymer, chitosan, as smart material platforms for curcumin delivery. Chitosan was used as the backbone material to be grafted with poly-(N-isopropylacrylamide) (pNIPAM) using an EDC/NHS coupling reaction. The conjugated products were characterized by 1H NMR and TGA. Chitosan-grafted pNIPAM (CS-g-pN) nanogels were prepared by a sonication method. The loading of curcumin into the CS-g-pN nanogels was achieved using an incubation method. Size, morphology of nanogels, amounts of curcumin loaded to the nanogels and cellular uptake were investigated by DLS, TEM, fluorescent spectroscopy and confocal microscopy techniques, respectively. A CellTiter-Blue® cell viability assay was performed in NIH-3T3 and HeLa cells to assess the safety while MTT assay was carried out in MDA-231, Caco-2, HepG2, and HT-29 cells for determining cytotoxic effects. Results showed that CS-g-pN with 3-60% degree of modification were simply assembled into spherical nanogel particles with submicron sizes, in which curcumin was encapsulated. The thermoresponsive behavior of each CS-g-pN nanogel formulation differed due to the grafted pNIPAM length and density. The CS-g-pN nanogel formulations were non-toxic towards NIH-3T3 and HeLa cells. Each curcumin-loaded CS-g-pN nanogel formulation could be up taken into NIH-3T3 cell lines and showed the dose-dependent cytotoxicity against tested cell lines. Successful development of this curcumin-loaded nanogel will lead to advanced materials that can be functionalized and optimized for targeted therapy and controlled delivery of small molecules and/or biomolecules for biomedical applications.
Collapse
Affiliation(s)
- Jittima Amie Luckanagul
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Chulalongkorn University Drug and Health Products Innovation & Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Chutamart Pitakchatwong
- The Petroleum and Petrochemical College, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Pahweenvaj Ratnatilaka Na Bhuket
- Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Biomedicinal Chemistry Program, Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Chawanphat Muangnoi
- Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Pharmaceutical Chemistry and Natural Products Program, Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Pranee Rojsitthisak
- Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Metallurgy and Materials Science Research Institute, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Suwabun Chirachanchai
- The Petroleum and Petrochemical College, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Center for Petroleum and Petrochemical, and Advanced Materials, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Center of Innovation Nanomaterial, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand
| | - Qian Wang
- 631 Sumter St., Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, 29208, USA
| | - Pornchai Rojsitthisak
- Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand; Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand.
| |
Collapse
|
137
|
Xie J, Li Y, Song L, Pan Z, Ye S, Hou Z. Design of a novel curcumin-soybean phosphatidylcholine complex-based targeted drug delivery systems. Drug Deliv 2017; 24:707-719. [PMID: 28436718 PMCID: PMC8241017 DOI: 10.1080/10717544.2017.1303855] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Revised: 02/26/2017] [Accepted: 03/05/2017] [Indexed: 01/03/2023] Open
Abstract
Recently, the global trend in the field of nanomedicine has been toward the design of combination of nature active constituents and phospholipid (PC) to form a therapeutic drug-phospholipid complex. As a particular amphiphilic molecular complex, it can be a unique bridge of traditional dosage-form and novel drug delivery system. In thisarticle, on the basis of drug-phospholipid complex technique and self-assembly technique, we chose a pharmacologically safe and low toxic drug curcumin (CUR) to increase drug-loading ability, achieve controlled/sustained drug release and improve anticancer activity. A novel CUR-soybean phosphatidylcholine (SPC) complex and CUR-SPC complex self-assembled nanoparticles (CUR-SPC NPs) were prepared by a co-solvent method and a nanoprecipitation method. DSPE-PEG-FA was further functionalized on the surface of PEG-CUR-SPC NPs (designed as FA-PEG-CUR-SPC NPs) to specifically increase cellular uptake and targetability. The FA-PEG-CUR-SPC NPs showed a spherical shape, a mean diameter of about 180 nm, an excellent physiological stability and pH-triggered drug release. The drug entrapment efficiency and drug-loading content was up to 92.5 and 16.3%, respectively. In vitro cellular uptake and cytotoxicity studies demonstrated that FA-PEG-CUR-SPC NPs and CUR-SPC NPs presented significantly stronger cellular uptake efficacy and anticancer activity against HeLa cells and Caco-2 cells compared to free CUR, CUR-SPC NPs and PEG-CUR-SPC NPs. More importantly, FA-PEG-CUR-SPC NPs showed the prolonged systemic circulation lifetime and enhanced tumor accumulation compared with free CUR and PEG-CUR-SPC NPs. These results suggest that the FA targeted PEGylated CUR-SPC complex self-assembled NPs might be a promising candidate in cancer therapy.
Collapse
Affiliation(s)
- Jiajiang Xie
- Xiamen Xianyue Hospital, Xiamen, China
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
| | - Yanxiu Li
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
| | - Liang Song
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
| | - Zhou Pan
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
| | - Shefang Ye
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
| | - Zhenqing Hou
- Department of Biomaterials, College of Materials, Xiamen University, Xiamen, China, and
- Department of Physics, Changji University, Changji, China
| |
Collapse
|
138
|
Delgado-Rivera SM, Pérez-Ortiz GE, Molina-Villarino A, Morales-Fontán F, García-Santos LM, González-Albó AM, Guadalupe AR, Montes-González I. Synthesis and characterization of novel ferrocenyl chalcone ammonium and pyridinium salt derivatives. Inorganica Chim Acta 2017; 468:245-251. [PMID: 29353916 PMCID: PMC5773109 DOI: 10.1016/j.ica.2017.07.050] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A novel series of ferrocenyl chalcone ammonium and pyridinium salt derivatives were synthesized in order to improve their solubility in aqueous media. Substituted ferrocenyl chalcones with amines and pyridines were synthesized using the base-catalyzed Claisen-Schmidt reaction, and their corresponding salts were prepared by a nucleophilic quaternization reaction at the nitrogen atom. Most of the synthesized ferrocenyl chalcone salts were soluble in water at room temperature. They were fully characterized by IR, NMR spectroscopy and HRMS spectrometry, and their electrochemistry was studied. The salt derivatives presented chemical reversibility, electrochemical quasi reversibility, and the slope of a plot of Log Ipc (or Ipa) versus Log v were almost 0.5 suggesting that their redox process was controlled by diffusion.
Collapse
Affiliation(s)
- Sara M. Delgado-Rivera
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Giovanny E. Pérez-Ortiz
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Andrés Molina-Villarino
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Fabiel Morales-Fontán
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Lyannis M. García-Santos
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Alma M. González-Albó
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Ana R. Guadalupe
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| | - Ingrid Montes-González
- Department of Chemistry, University of Puerto Rico, Río Piedras Campus, PO Box 23346 San Juan, PR 00931-3346
| |
Collapse
|
139
|
Rautio J, Kärkkäinen J, Sloan KB. Prodrugs – Recent approvals and a glimpse of the pipeline. Eur J Pharm Sci 2017; 109:146-161. [DOI: 10.1016/j.ejps.2017.08.002] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 08/01/2017] [Accepted: 08/02/2017] [Indexed: 01/12/2023]
|
140
|
Wiest J, Saedtler M, Balk A, Merget B, Widmer T, Bruhn H, Raccuglia M, Walid E, Picard F, Stopper H, Dekant W, Lühmann T, Sotriffer C, Galli B, Holzgrabe U, Meinel L. Mapping the pharmaceutical design space by amorphous ionic liquid strategies. J Control Release 2017; 268:314-322. [PMID: 29097303 DOI: 10.1016/j.jconrel.2017.10.040] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 10/27/2017] [Accepted: 10/28/2017] [Indexed: 01/12/2023]
Abstract
Poor water solubility of drugs fuels complex formulations and jeopardizes patient access to medication. Simplifying these complexities we systematically synthesized a library of 36 sterically demanding counterions and mapped the pharmaceutical design space for amorphous ionic liquid strategies for Selurampanel, a poorly water soluble drug used against migraine. Patients would benefit from a rapid uptake after oral administration to alleviate migraine symptoms. Therefore, we probed the ionic liquids for the flux, supersaturation period and hygroscopicity leading to algorithms linking molecular counterion descriptors to predicted pharmaceutical outcome. By that, 30- or 800-fold improvements of the supersaturation period and fluxes were achieved as were immediate to sustained release profiles through structural counterions' optimization compared to the crystalline free acid of Selurampanel. Guided by ionic liquid structure, in vivo profiles ranged from rapid bioavailability and high maximal plasma concentrations to sustained patterns. In conclusion, the study outlined and predicted the accessible pharmaceutical design space of amorphous ionic liquid based and excipient-free formulations pointing to the enormous pharmaceutical potential of ionic liquid designs.
Collapse
Affiliation(s)
- Johannes Wiest
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Marco Saedtler
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Anja Balk
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Benjamin Merget
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Toni Widmer
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Heike Bruhn
- Institute for Molecular Infection Biology (IMIB), Josef-Schneider-Straße 2, 97080 Würzburg, Germany
| | - Marc Raccuglia
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Elbast Walid
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Franck Picard
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Helga Stopper
- Department of Toxicology, Institute for Pharmacology and Toxicology, Versbacher Straße 9, 97078 Würzburg, Germany
| | - Wolfgang Dekant
- Department of Toxicology, Institute for Pharmacology and Toxicology, Versbacher Straße 9, 97078 Würzburg, Germany
| | - Tessa Lühmann
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Christoph Sotriffer
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Bruno Galli
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Ulrike Holzgrabe
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Lorenz Meinel
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany.
| |
Collapse
|
141
|
Abstract
Covalent modification of therapeutic compounds is a clinically proven strategy to devise prodrugs with enhanced treatment efficacies. This prodrug strategy relies on the modified drugs that possess advantageous pharmacokinetic properties and administration routes over their parent drug. Self-assembling prodrugs represent an emerging class of therapeutic agents capable of spontaneously associating into well-defined supramolecular nanostructures in aqueous solutions. The self-assembly of prodrugs expands the functional space of conventional prodrug design, affording a possible pathway to more effective therapies as the assembled nanostructure possesses distinct physicochemical properties and interaction potentials that can be tailored to specific administration routes and disease treatment. In this review, we will discuss the various types of self-assembling prodrugs in development, providing an overview of the methods used to control their structure and function and, ultimately, our perspective on their current and future potential.
Collapse
Affiliation(s)
- Andrew G Cheetham
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Eastern Road, Zhengzhou 450052, Henan, China
| | | | | | | |
Collapse
|
142
|
Zhu C, Wang R, Zheng W, Chen D, Yue X, Cao Y, Qin W, Sun H, Wang Y, Liu Z, Li B, Du J, Bu X, Zhou B. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo. Biomed Pharmacother 2017; 96:551-562. [PMID: 29032339 DOI: 10.1016/j.biopha.2017.10.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Revised: 09/14/2017] [Accepted: 10/02/2017] [Indexed: 12/14/2022] Open
Abstract
Major limitations of chalcones as clinical anticancer agents are water insolubility and poor bioavailability, which may be improved by a classic phosphate prodrug strategy that targets non-specific alkaline phosphatase (ALP) for releasing the parent drug in vivo. In this study, we found that BOC26P, a phosphate prodrug of chalcone OC26, exhibits excellent water solubility and improved plasma concentration in vivo by either i.v. or p.o. compared with the parent drug. In pace with decreased inhibitory activity of BOC26P against microtubule polymerization in vitro and in cells, the antiproliferative activity of BOC26P is attenuated in A549 and HLF cells. However, the antitumor effect of BOC26P increases in an A549 xenograft model as compared to the equimolar concentration of OC26, suggesting that complex tumor microenvironment would be another important influence factor to regulate the antitumor activity of BOC26Pin vivo. In conclusion, these observations showed that the traditional phosphate prodrug strategy would be a promising and easy method to increase water solubility and anticancer activity of chalcones for the clinical developments of anticancer agents.
Collapse
Affiliation(s)
- Cuige Zhu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Ruimin Wang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China; Department of Nuclear Medicine, Guangzhou General Hospital of Guangzhou Military Command Guangzhou, Guangdong, 510010, PR China
| | - Weichao Zheng
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Daoyuan Chen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Xin Yue
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Yingnan Cao
- School of Pharmacy, Xinhua College of Sun Yat-sen University, Guangzhou, PR China
| | - Wenjing Qin
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Haixia Sun
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Youqiao Wang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Ziyi Liu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Baojian Li
- Shenzhen Davoos tech. Ltd.Co., Room A611, Silver star tech. building, 1301 Guanguang Road, Guanlan, Longhua District, Shenzhen, PR China
| | - Jun Du
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Xianzhang Bu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Binhua Zhou
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China.
| |
Collapse
|
143
|
Chaudhari SP, Dugar RP. Application of surfactants in solid dispersion technology for improving solubility of poorly water soluble drugs. J Drug Deliv Sci Technol 2017. [DOI: 10.1016/j.jddst.2017.06.010] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
144
|
Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Adv Drug Deliv Rev 2017; 118:65-77. [PMID: 28676386 DOI: 10.1016/j.addr.2017.06.013] [Citation(s) in RCA: 176] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 06/27/2017] [Accepted: 06/29/2017] [Indexed: 12/21/2022]
Abstract
Prodrugs are cunning derivatives of therapeutic agents designed to improve the pharmacokinetics profile of the drug. Within a prodrug, pharmacological activity of the drug is masked and is recovered within the human body upon bioconversion of the prodrug, a process that is typically mediated by enzymes. This concept is highly successful and a significant fraction of marketed therapeutic formulations is based on prodrugs. An advanced subset of prodrugs can be engineered such as to achieve site-specific bioconversion of the prodrug - to comprise the highly advantageous "enzyme prodrug therapy", EPT. Design of prodrugs for EPT is similar to the prodrugs in general medicinal use in that the pharmacological activity of the drug is masked, but differs significantly in that site-specific bioconversion is a prime consideration, and the enzymes typically used for EPT are non-mammalian and/or with low systemic abundance in the human body. This review focuses on the design of prodrugs for EPT in terms of the choice of an enzyme and the corresponding prodrug for bioconversion. We also discuss the recent success of "self immolative linkers" which significantly empower and diversify the prodrug design, and present methodologies for the design of prodrugs with extended blood residence time. The review aims to be of specific interest for medicinal chemists, biomedical engineers, and pharmaceutical scientists.
Collapse
|
145
|
Du B, Li D, Wang J, Wang E. Designing metal-contained enzyme mimics for prodrug activation. Adv Drug Deliv Rev 2017; 118:78-93. [PMID: 28412325 DOI: 10.1016/j.addr.2017.04.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Revised: 03/22/2017] [Accepted: 04/04/2017] [Indexed: 01/09/2023]
Abstract
Enzyme-activated prodrug therapy (EAPT) is a widely-used and effective treatment method for cancer by converting prodrugs into drugs at the demanded time and space, whose key step is prodrug activation. Traditional prodrug activations are mostly dependent on natural enzymes, which are unstable, expensive and hard to be functionalized. The emerging enzyme mimics, especially the metal-contained enzyme mimics (MEMs), provide a potential chance for improving the traditional EAPT because of their high stability, low cost and easiness of preparation and functionalization. The existing MEMs can be classified into three categories: catalytic core-scaffold MEM (csMEM), nanoparticle MEM (npMEMs) and metal-organic framework (MOF) MEM (mofMEM). These MEMs can mimic diverse functions corresponding to natural enzymes, and some of which are potentially used in prodrug activation, such as DNase, RNase, carbonate esterase, etc. In this review, we briefly summarize the MEMs according to their structure and composition, and highlight the successful and potential applications for prodrug activation mediated by hydrolase-like and oxidoreductase-like MEMs.
Collapse
|
146
|
Liu G, Lin Q, Huang Y, Guan G, Jiang Y. Tailoring the particle microstructures of gefitinib by supercritical CO 2 anti-solvent process. J CO2 UTIL 2017. [DOI: 10.1016/j.jcou.2017.04.015] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
147
|
Click strategy using disodium salts of amino acids improves the water solubility of plinabulin and KPU-300. Bioorg Med Chem 2017; 25:3623-3630. [DOI: 10.1016/j.bmc.2017.04.024] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2017] [Revised: 04/14/2017] [Accepted: 04/18/2017] [Indexed: 02/08/2023]
|
148
|
Freire MCLC, Alexandrino F, Marcelino HR, Picciani PHDS, Silva KGDHE, Genre J, Oliveira AGD, Egito ESTD. Understanding Drug Release Data through Thermodynamic Analysis. MATERIALS (BASEL, SWITZERLAND) 2017; 10:E651. [PMID: 28773009 PMCID: PMC5554032 DOI: 10.3390/ma10060651] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 05/13/2017] [Accepted: 05/18/2017] [Indexed: 11/29/2022]
Abstract
Understanding the factors that can modify the drug release profile of a drug from a Drug-Delivery-System (DDS) is a mandatory step to determine the effectiveness of new therapies. The aim of this study was to assess the Amphotericin-B (AmB) kinetic release profiles from polymeric systems with different compositions and geometries and to correlate these profiles with the thermodynamic parameters through mathematical modeling. Film casting and electrospinning techniques were used to compare behavior of films and fibers, respectively. Release profiles from the DDSs were performed, and the mathematical modeling of the data was carried out. Activation energy, enthalpy, entropy and Gibbs free energy of the drug release process were determined. AmB release profiles showed that the relationship to overcome the enthalpic barrier was PVA-fiber > PVA-film > PLA-fiber > PLA-film. Drug release kinetics from the fibers and the films were better fitted on the Peppas-Sahlin and Higuchi models, respectively. The thermodynamic parameters corroborate these findings, revealing that the AmB release from the evaluated systems was an endothermic and non-spontaneous process. Thermodynamic parameters can be used to explain the drug kinetic release profiles. Such an approach is of utmost importance for DDS containing insoluble compounds, such as AmB, which is associated with an erratic bioavailability.
Collapse
Affiliation(s)
| | - Francisco Alexandrino
- Programa de Pós-graduaçãoem Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
| | - Henrique Rodrigues Marcelino
- Programa de Pós-graduaçãoem Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
| | | | | | - Julieta Genre
- Programa de Pós-graduaçãoem Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
| | - Anselmo Gomes de Oliveira
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara-SP 14800-903, Brazil.
| | - Eryvaldo Sócrates Tabosa do Egito
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
- Programa de Pós-graduaçãoem Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
- Programa de Pós-graduaçãoem Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal-RN 59012-570, Brazil.
| |
Collapse
|
149
|
Seo JW, Hwang KM, Lee SH, Kim DW, Park ES. Preparation and characterization of adefovir dipivoxil-stearic acid cocrystal with enhanced physicochemical properties. Pharm Dev Technol 2017; 23:890-899. [PMID: 28535125 DOI: 10.1080/10837450.2017.1334664] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The objectives of this study were to prepare cocrystal composed of adefovir dipivoxil (AD) and stearic acid (SA) and to investigate the enhanced properties of the cocrystal. The cocrystal was prepared by antisolvent precipitation and characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRPD), and differential scanning calorimetry (DSC). The enhanced properties were evaluated by dissolution testing, permeability studies, and powder rheology analysis. The AD raw material has a cuboid-like crystal and the cocrystal has a needle shape. In the FT-IR study, there were bathochromic shifts caused by the hydrogen bonding. The melting point of the cocrystal was 52.9 °C, which was lower than that of AD. The XRPD pattern also had distinct differences, supporting the formation of a new crystalline form. The cocrystal showed changes in the lattice energy and the solvation strength, which caused an enhanced dissolution. The permeability was increased due to the SA, which acts as a P-gp inhibitor. The tabletability was enhanced due to the altered crystal habit. In conclusion, cocrystal containing AD and SA was successfully prepared, presenting advantages such as enhanced solubility, tabletability, and permeability. The use of the cocrystal is a desirable approach for the improved physicochemical properties.
Collapse
Affiliation(s)
- Jeong-Woong Seo
- a School of Pharmacy , Sungkyunkwan University , Suwon , Republic of Korea
| | - Kyu-Min Hwang
- a School of Pharmacy , Sungkyunkwan University , Suwon , Republic of Korea
| | - Sung-Hoon Lee
- b Department of Pharmaceutical Engineering , Cheongju University , Cheongju , Republic of Korea
| | - Dong-Wook Kim
- b Department of Pharmaceutical Engineering , Cheongju University , Cheongju , Republic of Korea
| | - Eun-Seok Park
- a School of Pharmacy , Sungkyunkwan University , Suwon , Republic of Korea
| |
Collapse
|
150
|
Göke K, Lorenz T, Repanas A, Schneider F, Steiner D, Baumann K, Bunjes H, Dietzel A, Finke JH, Glasmacher B, Kwade A. Novel strategies for the formulation and processing of poorly water-soluble drugs. Eur J Pharm Biopharm 2017; 126:40-56. [PMID: 28532676 DOI: 10.1016/j.ejpb.2017.05.008] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/10/2017] [Accepted: 05/15/2017] [Indexed: 12/31/2022]
Abstract
Low aqueous solubility of active pharmaceutical ingredients presents a serious challenge in the development process of new drug products. This article provides an overview on some of the current approaches for the formulation of poorly water-soluble drugs with a special focus on strategies pursued at the Center of Pharmaceutical Engineering of the TU Braunschweig. These comprise formulation in lipid-based colloidal drug delivery systems and experimental as well as computational approaches towards the efficient identification of the most suitable carrier systems. For less lipophilic substances the preparation of drug nanoparticles by milling and precipitation is investigated for instance by means of microsystem-based manufacturing techniques and with special regard to the preparation of individualized dosage forms. Another option to overcome issues with poor drug solubility is the incorporation into nanospun fibers.
Collapse
Affiliation(s)
- Katrin Göke
- Technische Universität Braunschweig, Institut für Pharmazeutische Technologie, Mendelssohnstr. 1, 38106 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Thomas Lorenz
- Technische Universität Braunschweig, Institut für Mikrotechnik, Alte Salzdahlumer Str. 203, 38124 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Alexandros Repanas
- Leibniz Universität Hannover, Institut für Mehrphasenprozesse, Callinstr. 36, 30167 Hannover, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Frederic Schneider
- Technische Universität Braunschweig, Institut für Medizinische und Pharmazeutische Chemie, Beethovenstr. 55, 38106 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Denise Steiner
- Technische Universität Braunschweig, Institut für Partikeltechnik, Volkmaroder Str. 5, 38104 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Knut Baumann
- Technische Universität Braunschweig, Institut für Medizinische und Pharmazeutische Chemie, Beethovenstr. 55, 38106 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Heike Bunjes
- Technische Universität Braunschweig, Institut für Pharmazeutische Technologie, Mendelssohnstr. 1, 38106 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Andreas Dietzel
- Technische Universität Braunschweig, Institut für Mikrotechnik, Alte Salzdahlumer Str. 203, 38124 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Jan H Finke
- Technische Universität Braunschweig, Institut für Partikeltechnik, Volkmaroder Str. 5, 38104 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Birgit Glasmacher
- Leibniz Universität Hannover, Institut für Mehrphasenprozesse, Callinstr. 36, 30167 Hannover, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| | - Arno Kwade
- Technische Universität Braunschweig, Institut für Partikeltechnik, Volkmaroder Str. 5, 38104 Braunschweig, Germany; Technische Universität Braunschweig, Zentrum für Pharmaverfahrenstechnik (PVZ), Franz-Liszt-Str. 35a, 38106 Braunschweig, Germany.
| |
Collapse
|